Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

In Fight Against Superbugs, BARDA Looks to Shore Up National Stockpile Countermeasures

by Global Biodefense Staff
June 18, 2019
Illustrative representation of MRSA - Antibiotic Resistance

Credit: Shutterstock

A crisis has arisen from the simultaneous decrease in the number of pharmaceutical companies developing antibiotics and the dramatic increase in the prevalence of infections and deaths caused by antibiotic resistant pathogens. Due to the genetic promiscuity of bacteria, the same genetic markers that give rise to antibiotic resistance in hospital acquired infections can be transferred to biothreat pathogens (e.g. Y. pestis, B. anthracis, F. tularensis, B. mallei and/or B. pseudomallei).

Therefore, the threat of naturally-occurring or intentionally-engineered antibiotic-resistant biothreat pathogens potentially impacts the effectiveness of the current stockpile of antibiotic medical countermeasures (MCMs) to treat these threats.

The year-over-year increase in hospital and community acquired bacterial infections due to antibiotic resistant bacteria and the transmissibility of these resistant markers to sensitive bacteria represents a serious threat to the national health security of the United States. These health challenges also place a substantial health and economic burden on our society and will continue to do so if not adequately addressed.

Using Project BioShield funds, the Biomedical Advanced Research and Development Authority (BARDA) seeks to develop candidate antibiotics which have received marketing authorization from the U.S. Food and Drug Administration (FDA) for a pulmonary indication or are in Phase 3 clinical development for a pulmonary indication, and eligible for Emergency Use Authorization (EUA) pre-approval by FDA for a biothreat indication. If the antibiotic does not have FDA marketing authorization for a pulmonary indication, the Offeror must seek development and FDA marketing authorization for a pulmonary indication that could support EUA pre-approval or marketing authorization for a biothreat indication.

BARDA will also support the necessary late-stage development to complete the regulatory pathway for a biothreat indication for the antibiotics being procured (if applicable) and efforts related to post-marketing commitments.

Supporting the development and stockpiling of medical countermeasures that treat antibiotic resistant bacteria including biothreats will augment the U.S. response to any biothreat agent or public health emergency.

Additional details are available via Solicitation Number: 19-100-SOL-00011.

Source: FBO.gov

Tags: Antibiotic ResistanceAntimicrobialsASPRBARDADrug DevelopmentEditor PickEmergency Use AuthorizationHHSRequest for ProposalsStrategic National Stockpile

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC